JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265117

Human HNRNPDL knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

HNRNPDL KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 38 bp deletion in exon 1 and 47 bp deletion in exon 1.

View Alternative Names

A+U-rich element RNA binding factor, AA407431, AA959857, AU-rich element RNA-binding factor, D5Ertd650e, D5Wsu145e, HNRDL_HUMAN, HNRNP, Heterogeneous nuclear ribonucleoprotein D like protein, Heterogeneous nuclear ribonucleoprotein D-like, JKT41-binding protein, JKTBP, JKTBP2, MGC125262, Protein laAUF1, hnHNRP DL, hnRNP D-like, hnRNP DL, hnRPD like protein, laAUF1

2 Images
Sanger Sequencing - Human HNRNPDL knockout HeLa cell line (AB265117)
  • Sanger seq

Unknown

Sanger Sequencing - Human HNRNPDL knockout HeLa cell line (AB265117)

Allele-1 : 47 bp deletion in exon 1.

Sanger Sequencing - Human HNRNPDL knockout HeLa cell line (AB265117)
  • Sanger seq

Unknown

Sanger Sequencing - Human HNRNPDL knockout HeLa cell line (AB265117)

Allele-2 : 38 bp deletion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 38 bp deletion in exon 1 and 47 bp deletion in exon 1

Disease

Adenocarcinoma

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265117-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265117 Human HNRNPDL knockout HeLa cell line", "number":"AB265117-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265117-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265117 Human HNRNPDL knockout HeLa cell line", "number":"AB265117-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
HNRNPDL
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

HNRPDL also known as heterogeneous nuclear ribonucleoprotein D-like is a protein with a mass of about 42 kDa. It plays an important role in RNA processing activities like splicing transportation stabilization and degradation. The protein is part of the hnRNP family which contains versatile nucleic acid-binding proteins involved in various aspects of mRNA processing and metabolism. HNRPDL is expressed in multiple tissues including high levels in muscle heart and brain indicating its broad functional importance.
Biological function summary

HnRNP D-like protein participates in regulating gene expression post-transcriptionally. It often forms a complex with other hnRNP proteins enabling the modulation of RNA metabolic processes. This protein binds to RNA through its nucleic acid-binding domains influencing the mRNA stability and pre-mRNA processing. It affects various cellular processes by regulating gene transcripts vital for maintaining normal cellular functions.

Pathways

HnRNP D-like protein is part of key processes that influence mRNA splicing and transport. It is involved in the mRNA surveillance pathway that monitors and degrades abnormal mRNA molecules. HNRPDL also interacts with other proteins like HNRNPA1 in these pathways showing its importance in RNA regulation and cellular homeostasis. Its function in these pathways suggests it plays a role in ensuring the accuracy of mRNA synthesis and processing.

Altered HNRPDL function is linked to conditions such as myopathy and some neurodegenerative diseases. Mutations or dysregulation in hnRNP D-like protein can affect muscle tissues and might contribute to muscle degeneration disorders. Additionally its abnormal function may also relate to neurological disorders potentially through pathways that involve other hnRNP family members like HNRNPA1. Understanding its connection to these diseases could provide insights into potential therapeutic targets for related conditions.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com